Guides
Plain-English explainers on how these medications work, how they compare, and how to access them. Evergreen reference, updated as the science and the market change.
Compare the medications
Semaglutide vs Tirzepatide
How the two leading GLP-1s compare on results, cost, and side effects.
What Is Retatrutide?
The triple-receptor agonist posting ~24% weight loss in trials.
What Is CagriSema?
Semaglutide plus an amylin analog hitting two satiety systems.
The GLP-1 Pill
How oral GLP-1s compare to injections, and who they suit.
Access, cost & eligibility
How to Qualify for Semaglutide
BMI thresholds and what the online intake actually checks.
GLP-1 Cost & Eligibility Cheat Sheet
One page: real monthly costs, who qualifies, and what to ask before you pay.
What Is a Compounding Pharmacy?
How compounding pharmacies work and how they are regulated.
Compounded GLP-1s in 2026
What stays accessible after the 2026 compounding crackdown.
More
Oral Semaglutide vs Orforglipron
Wegovy pill showed 16.6% weight loss vs 12.4% for Foundayo, but no fasting window required.
What Is Amycretin?
Novo Nordisk's GLP-1/amylin dual agonist posted 24.3% weight loss in Phase 2. Phase 3 AMAZE trials started February 2026.
Retatrutide vs CagriSema
TRIUMPH-1: retatrutide 28.3% weight loss at 80 weeks. REDEFINE 1: CagriSema 22.7% at 68 weeks. No head-to-head trial between them exists yet.
Survodutide vs Retatrutide
Both drugs use a glucagon receptor; retatrutide adds GIP on top. TRIUMPH-1: 28.3% weight loss vs SYNCHRONIZE-1: 16.6%. Neither drug is approved.
What Is CX11?
Corxel's oral GLP-1 pill CX11 posted 11.5% weight loss at 36 weeks in Phase 2, with no fasting window required.
What Is Eloralintide?
Lilly's amylin-only obesity drug skips GLP-1 entirely and posted 9.5-20.1% weight loss in Phase 2, with favorable GI tolerability.
What Is KAI-7535?
Hengrui/Kailera's oral GLP-1 pill posted 10.9-11.1% weight loss in Phase 3, but nausea (70%) and vomiting (up to 68.6%) ran far above rival pills.
What Is Petrelintide?
Zealand and Roche's amylin-only obesity drug posted 10.7% weight loss in Phase 2 with placebo-like tolerability. Roche paid $1.65B upfront for it.
Survodutide vs Tirzepatide
Survodutide cut liver fat 63% and visceral fat 34% in Phase 3. Tirzepatide hit 20.9% weight loss. How the two dual agonists actually compare.
Retatrutide vs Tirzepatide
TRIUMPH-1: retatrutide 28.3% weight loss at 80 weeks vs tirzepatide 20.9% at 72 weeks. The largest efficacy gap in Phase 3 obesity drug history.
